Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Prostate Cancer

  Free Subscription


16.08.2021

1 BJU Int
1 BMC Cancer
1 BMC Urol
1 Cancer
1 Cancer Lett
1 Cancer Res
1 Clin Cancer Res
1 Eur Radiol
1 Eur Urol
1 Int J Urol
1 J Nucl Med
2 Lancet Oncol
1 Nat Rev Urol
1 PLoS One
1 Proc Natl Acad Sci U S A
1 Prostate
2 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    BJU Int

  1. DOAN P, Graham P, Lahoud J, Remmers S, et al
    A comparison of prostate cancer prediction models in men undergoing both magnetic resonance imaging and transperineal biopsy: Are the models still relevant?
    BJU Int. 2021 Aug 9. doi: 10.1111/bju.15554.
    PubMed         Abstract available


    BMC Cancer

  2. ORTIZ-OTERO N, Marshall JR, Glenn A, Matloubieh J, et al
    TRAIL-coated leukocytes to kill circulating tumor cells in the flowing blood from prostate cancer patients.
    BMC Cancer. 2021;21:898.
    PubMed         Abstract available


    BMC Urol

  3. MIYASAKA Y, Kawamura H, Sato H, Kubo N, et al
    Carbon ion radiotherapy for prostate cancer with bladder invasion.
    BMC Urol. 2021;21:106.
    PubMed         Abstract available


    Cancer

  4. NECCHI A, Cucchiara V, Grivas P, Bratslavsky G, et al
    Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer.
    Cancer. 2021 Aug 11. doi: 10.1002/cncr.33865.
    PubMed         Abstract available


    Cancer Lett

  5. LI Q, Ye L, Zhang X, Wang M, et al
    Corrigendum to "FZD8, a target of p53, promotes bone metastasis in prostate cancer by activating canonical Wnt/beta-catenin signaling" [Cancer Lett. 402 (2017) 166-176].
    Cancer Lett. 2021 Aug 3. pii: S0304-3835(21)00383.
    PubMed        


    Cancer Res

  6. BUTLER LM, Mah CY, Machiels J, Vincent AD, et al
    Lipidomic profiling of clinical prostate cancer reveals targetable alterations in membrane lipid composition.
    Cancer Res. 2021 Aug 6. pii: 0008-5472.CAN-20-3863.
    PubMed         Abstract available


    Clin Cancer Res

  7. RESCIGNO P, Gurel B, Pereira R, Crespo M, et al
    Characterizing CDK12-Mutated Prostate Cancers.
    Clin Cancer Res. 2021;27:566-574.
    PubMed         Abstract available


    Eur Radiol

  8. JENTJENS S, Mai C, Ahmadi Bidakhvidi N, De Coster L, et al
    Prospective comparison of simultaneous [(68)Ga]Ga-PSMA-11 PET/MR versus PET/CT in patients with biochemically recurrent prostate cancer.
    Eur Radiol. 2021 Aug 10. pii: 10.1007/s00330-021-08140.
    PubMed         Abstract available


    Eur Urol

  9. LORENTE D, Llacer C, Lozano R, de Velasco G, et al
    Prognostic Score and Benefit from Abiraterone in First-line Metastatic, Castration-resistant Prostate Cancer.
    Eur Urol. 2021 Aug 6. pii: S0302-2838(21)01917.
    PubMed         Abstract available


    Int J Urol

  10. MAESAKA F, Tanaka N, Nakai Y, Asakawa I, et al
    Comparison of disease-specific quality of life in prostate cancer patients treated with low-dose-rate brachytherapy: A randomized controlled trial of silodosin versus naftopidil.
    Int J Urol. 2021 Aug 10. doi: 10.1111/iju.14667.
    PubMed         Abstract available


    J Nucl Med

  11. SANDHU S, Guo C, Hofman MS
    Radionuclide Therapy in Prostate Cancer: from standalone to combination PSMA theranostics.
    J Nucl Med. 2021 Aug 12. pii: jnumed.120.243295. doi: 10.2967/jnumed.120.243295.
    PubMed         Abstract available


    Lancet Oncol

  12. CONTEDUCA V, De Giorgi U
    Talazoparib: a new biomarker-directed therapy in advanced prostate cancer.
    Lancet Oncol. 2021 Aug 10. pii: S1470-2045(21)00450.
    PubMed        

  13. DE BONO JS, Mehra N, Scagliotti GV, Castro E, et al
    Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
    Lancet Oncol. 2021 Aug 10. pii: S1470-2045(21)00376.
    PubMed         Abstract available


    Nat Rev Urol

  14. ZAORSKY NG, Calais J, Fanti S, Tilki D, et al
    Salvage therapy for prostate cancer after radical prostatectomy.
    Nat Rev Urol. 2021 Aug 6. pii: 10.1038/s41585-021-00497.
    PubMed         Abstract available


    PLoS One

  15. CHO D, Milbury K, Liao Y, Pettaway CA, et al
    Study protocol: One plus one can be greater than two-Ecological momentary assessment for Black prostate cancer survivors and partners.
    PLoS One. 2021;16:e0255614.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A


  16. Correction for Baek et al., Ligand-specific allosteric regulation of coactivator functions of androgen receptor in prostate cancer cells.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed        


    Prostate

  17. NANDALUR KR, Colvin R, Walker D, Nandalur SR, et al
    Benign prostate hyperplasia as a potential protective factor against prostate cancer: Insights from a magnetic resonance imaging study of compositional characteristics.
    Prostate. 2021 Aug 10. doi: 10.1002/pros.24207.
    PubMed         Abstract available


    Urology

  18. BERG RNWV, Basourakos SP, Shoag J, Scherr D, et al
    Prostate Cancer Screening for Gay Men in the United States.
    Urology. 2021 Aug 8. pii: S0090-4295(21)00734.
    PubMed         Abstract available

  19. JAMIESON SC, Mallory CW, Jivanji DR, Perez A, et al
    THE ROLE OF HEALTH LITERACY IN PROSTATE CANCER SCREENING.
    Urology. 2021 Aug 7. pii: S0090-4295(21)00735.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: